283 related articles for article (PubMed ID: 26755179)
21. Breakthrough pain in patients with head & neck cancer. A secondary analysis of IOPS MS study.
Mercadante S; Masedu F; Valenti M; Aielli F
Oral Oncol; 2019 Aug; 95():87-90. PubMed ID: 31345399
[TBL] [Abstract][Full Text] [Related]
22. How nurses assess breakthrough cancer pain, and the impact of this pain on patients' daily lives--results of a European survey.
Rustøen T; Geerling JI; Pappa T; Rundström C; Weisse I; Williams SC; Zavratnik B; Wengström Y
Eur J Oncol Nurs; 2013 Aug; 17(4):402-7. PubMed ID: 23276599
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment.
Cortesi PA; D'Angiolella LS; Vellucci R; Allegri M; Casale G; Favaretti C; Kheiraoui F; Cesana G; Mantovani LG
PLoS One; 2017; 12(6):e0179523. PubMed ID: 28654672
[TBL] [Abstract][Full Text] [Related]
24. Diagnosis and management of breakthrough cancer pain: Have all the questions been resolved? A Delphi-based consensus assessment (DOIRON).
Porta-Sales J; Pérez C; Escobar Y; Martínez V
Clin Transl Oncol; 2016 Sep; 18(9):945-54. PubMed ID: 26693731
[TBL] [Abstract][Full Text] [Related]
25. Non pharmacological interventions and non-fentanyl pharmacological treatments for breakthrough cancer pain: A systematic and critical review.
Mercadante S
Crit Rev Oncol Hematol; 2018 Feb; 122():60-63. PubMed ID: 29458790
[TBL] [Abstract][Full Text] [Related]
26. Breakthrough Cancer Pain in Patients Receiving Low Doses of Opioids for Background Pain.
Mercadante S; Caraceni A; Masedu F; Scipioni T; Aielli F
Oncologist; 2020 Feb; 25(2):156-160. PubMed ID: 31862860
[TBL] [Abstract][Full Text] [Related]
27. Knowledge and practice of the management of breakthrough cancer pain among general practitioners providing palliative care in Shanghai, China: a cross-sectional survey.
Yu Y; Zhang P; Chen D; Jiang SF
BMJ Open; 2023 Sep; 13(9):e073670. PubMed ID: 37770268
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of sublingual fentanyl vs. oral morphine for cancer-related breakthrough pain.
Velázquez Rivera I; Muñoz Garrido JC; García Velasco P; España Ximénez de Enciso I; Velázquez Clavarana L
Adv Ther; 2014 Jan; 31(1):107-17. PubMed ID: 24385406
[TBL] [Abstract][Full Text] [Related]
29. Meaningful cut-off pain intensity for breakthrough pain changes in advanced cancer patients.
Mercadante S; Adile C; Torta R; Varetto A; Fulfaro F; Giarratano A; Casuccio A
Curr Med Res Opin; 2013 Jan; 29(1):93-7. PubMed ID: 23198976
[TBL] [Abstract][Full Text] [Related]
30. Lack of correlation between the effective dose of fentanyl sublingual spray for breakthrough cancer pain and the around-the-clock opioid dose.
Nalamachu SR; Parikh N; Dillaha L; Rauck R
J Opioid Manag; 2014; 10(4):247-54. PubMed ID: 25162604
[TBL] [Abstract][Full Text] [Related]
31. The use of rapid onset opioids for breakthrough cancer pain: the challenge of its dosing.
Mercadante S
Crit Rev Oncol Hematol; 2011 Dec; 80(3):460-5. PubMed ID: 21215653
[TBL] [Abstract][Full Text] [Related]
32. Breakthrough Cancer Pain Influences General Activities and Pain Management: A Comparison of Patients with and without Breakthrough Cancer Pain.
Tagami K; Okizaki A; Miura T; Watanabe YS; Matsumoto Y; Morita T; Fujimori M; Kinoshita H
J Palliat Med; 2018 Nov; 21(11):1636-1640. PubMed ID: 29975582
[TBL] [Abstract][Full Text] [Related]
33. Consensus and controversies in the definition, assessment, treatment and monitoring of BTcP: results of a Delphi study.
Boceta J; De la Torre A; Samper D; Farto M; Sánchez-de la Rosa R
Clin Transl Oncol; 2016 Nov; 18(11):1088-1097. PubMed ID: 26856600
[TBL] [Abstract][Full Text] [Related]
34. Breakthrough pain in patients with multiple myeloma: a secondary analysis of IOPS MS study.
Mercadante S; Caraceni A; Cuomo A; Mammucari M; Marchetti P; Mediati RD; Natoli S; Tonini G
Eur Rev Med Pharmacol Sci; 2023 Feb; 27(3):1134-1139. PubMed ID: 36808361
[TBL] [Abstract][Full Text] [Related]
35. Increased quality of life in patients with breakthrough cancer pain after individualized therapy: the CAVIDIOM study.
Villarroel PG; Padró JG; Marquina G; Jáñez NM; González EE; Antón A; Sánchez MB; Cáceres AR; López-López R; Cornejo RE; García PB; Fabregat RM; Fernández BC; Bermudo CL; Camps C
Future Oncol; 2022 Nov; 18(35):3913-3927. PubMed ID: 36537885
[TBL] [Abstract][Full Text] [Related]
36. Intranasal fentanyl spray: a novel dosage form for the treatment of breakthrough cancer pain.
Dietrich E; Gums JG
Ann Pharmacother; 2012 Oct; 46(10):1382-91. PubMed ID: 23012382
[TBL] [Abstract][Full Text] [Related]
37. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
38. Breakthrough cancer pain: twenty-five years of study.
Mercadante S; Portenoy RK
Pain; 2016 Dec; 157(12):2657-2663. PubMed ID: 27653423
[TBL] [Abstract][Full Text] [Related]
39. A European survey of oncology nurse breakthrough cancer pain practices.
Rustøen T; Geerling JI; Pappa T; Rundström C; Weisse I; Williams SC; Zavratnik B; Kongsgaard UE; Wengström Y
Eur J Oncol Nurs; 2013 Feb; 17(1):95-100. PubMed ID: 22742829
[TBL] [Abstract][Full Text] [Related]
40. Reply-Letter to the Editor: What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion.
; Vellucci R; Fanelli G; Cortesi PA; Pannuti R; Peruselli C; Romualdi P
Drugs; 2016 Jul; 76(10):1063-5. PubMed ID: 27324270
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
